Raquibul Hannan, MD, PhD

Curriculum Vitae

Date of preparation: August 2018

GENERAL INFORMATION

Office Address:            UT Southwestern Medical Center

                                    2280 Inwod Rd.

Dallas, Tx 75390-9183

Phone:(214) 645 7696

Fax:(214) 645 8527

Email:                          Raquibul.Hannan@utsouthwestern.edu

PRESENT POSTION:            Associate Professor of Radiation Oncology

                                                Associate Professor of Immunology

UT Southwestern Medical Center

                                                Simmons Cancer Center

EDUCATIONAL BACKGROUND

Undergraduate:

1996-1999       Bachelor of Arts (with Honors) in Biochemistry, New York University

Gradate:

1999-2006       Doctor of Medicine (MD), Downstate College of Medicine, State University of New York (SUNY) at Brooklyn   

1999-2006       Doctor of Philosophy (PhD), Downstate School of Graduate Studies, State University of New York (SUNY) at Brooklyn   

Internship:

2006-2007       Internal Medicine, SUNY Downstate Medical Center, Brooklyn, NY

Residency:

2007-2011       Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine

PROFESSIONAL POSITIONS AND EMPLOYMENT

Academic Positions

2006-2007       Clinical Assistant Instructor, Department of Internal Medicine, SUNY Downstate Medical Center, Brooklyn, NY

2007-2011       House Staff, Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine

2011-2017       Assistant Professor, Department of Radiation Oncology, UT Southwestern Medical Center

2017-Present    Associate Professor, Department of Radiation Oncology, UT Southwestern Medical Center

2017-Present    Associate Professor, Department of Immunology, UT Southwestern Medical Center

Hospital Positions

2006-2007       SUNY Downstate University Hospital, Brooklyn, NY

2006-2007       Kings County Hospital, Brooklyn, NY

2006-2007       VA Medical Center, Brooklyn, NY

2007-2011       Montefiore Medical Center, Bronx, NY

2007-2011       Albert Einstein Medical Center, Bronx, NY

2011-Present    St. Paul University Hospital, Dallas, Texas, 2011-present

2011-Present    Zale-Lipshy Hospital, Dallas, Texas, 2011-present

2011-Present    Parkland Memorial Hospital, Dallas, Texas, 2011-present

2015-Present    Clements University Hospital, Dallas, Texas, 2011-present

BOARD CERTIFICATIONS

2006          National Board of Medical Examiners-Board Certified Physician

2013          American Board of Radiology-Board Certified in Radiation Oncology

LICENSURE AND OTHER CERTIFICATIONS

Active Medical License: Texas, 2011-present

Federal Drug Enforcement Agency - Controlled Substance Registration

Texas Department of Public Safety - Controlled Substances Registration
Texas Medical Board – Licensed Physician

Accuray Corporation, Sunnyvale, CA – Certification of Training for Cyberknife radiosurgery

PROFESSIONAL SOCIETY MEMBERSHIPS

American Society of Therapeutic Radiation and Oncology (ASTRO)

Society for Immunotherapy of Cancer (SITC)

American Board of Radiology (ABR)

American College of Radiology (ACR)

Radiologic Society of North America (RSNA)

American Society of Clinical Oncology (ASCO)

New York Roentgen Society

HONORS AND AWARDS

• Alumni Association Summer Research Scholarship, Downstate Col. of Med., 2000
• Health Care in Developing Nations Scholarship, Downstate Col. of Med., 2005
• American Society of Therapeutic Radiation And Oncology, Poster Recognition Award in 52nd (2010) annual meeting
  70. In-Training Exam in Radiation Oncology question writer; 2014-present
  71. Research Scholar Grant; 2016
  50. Murchinson Foundation Award 2016.

COMMUNITY SERVICE

• Kidney Cancer Program co-leader
• Cancer Center GU DOT
• Radiation Oncology GU DOT: Team leader
• Medical School Admissions Committee Interviewer.
• NCI’s Renal cancer task force
• NRG GU core committee
• ASCO
• RSNA
• ASTRO
• Texas Radiological Society

ADMINISTRATIVE/LEADERSHIP POSITIONS

2011-Present    GU Disease Oriented Team Member, Simmons Cancer Center

2012-Present    Member, Simmons Cancer Center

2013-Present    Leader, GU Disease Oriented Team, Department of Radiation Oncology

2014-Present    Co-Leader, Kidney Cancer Program, Simmons Cancer Center

INVITED LECTURES

International:

• European Cancer Conference, Denmark, Copenhagen, 2003, “A Novel Pancreatic Cancer-Specific Tumor Marker: PaCa-Ag1”
• 1^st Central European Symposium on Radiation Oncology, Poland, Gliwice, 2014 “Tumor Immune-modulation by Radiation Therapy”
• 15^th International Kidney Cancer Symposium, Florida, 2016. “Utility of Radiation therapy for advanced RCC”
• Kidney Cancer Association Annual Meeting, Miami, Florida, October 2017. “Utility of Radiation Therapy for Advanced RCC”
• Paul Peters Symposium, Dallas, Texas, Feb 2018: “SBRT for Renal Malignancy”

National/Regional/Local:

• Urology Grand Rounds: “Indications for Adjuvant Radiation for Prostate Cancer” 2012
• Texas Radiological Society, Dallas, Texas, 2014 “Combining SBRT & Immunotherapy in GU Malignancies”
• Prostate cancer symposium, Simmons Cancer Center, Dallas, Texas 2013 “Exploiting the Immunogenic Properties of Radiation Therapy for Prostate Cancer Treatment”
• Simmons Cancer Center patient advocacy program: Man to Man,. “Application of Radiation Therapy for Prostate Cancer”; 2014.
• Kidney Cancer Program: “SAbR for the treatment of Kidney Cancer” 2015
• Hamon Center & Experimental Therapeutics of Cancer Program Conference: “i-SAbR: Exploiting the Immuno-modulatory Properties of Stereotactic Ablative Radiation.”2016
• American Society of Therapeutic Radiation and Oncology; “Phase II Trial of High Dose Interleukin-2 (IL-2) and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)—Interim Analysis of i-SAbR IL-2 Trial”; 2016.

Oral, Poster, Poster Discussion and Abstract presentations in national and international research conferences:

• American Society of Clinical Oncology: GU Cancer Symposium 2016
• American Society of Clinical Oncology: Breast Cancer Symposium 2009

•           American Society of Therapeutic Radiation And Oncology 2008, 2009, 2010, 2016

•           World Congress of Brachytherapy 2008

•           American Association of Cancer Research, San Francisco, CA, 2002

•           Molecular and Cell Biology Conference, Toronto, Canada, 2002

•           European Cancer Conference, Copenhagen, Denmark 2003

TECHNOLOGICAL AND OTHER SCIENTIFIC INNOVATIONS

”Pancreatic Cancer-Associated Antigen, Antibody thereto, and Diagnostic and Treatment Methods.”

J. Michl,M.D., S. Bradu,M.D.,Ph.D.,R. Hannan, M.D., PhD.

January 17, 2003. Patent Number: WO 2004/065547

“Pancreatic Cancer-Associated Antigen, Antibody thereto, and Diagnostic and Treatment Methods – Development of a PaCa-Ag1-Specific Enzyme-Linked Immuno-Assay.”

      J. Michl,M.D., S. Bradu,M.D.,Ph.D., R. Hannan, M.D., PhD, M.R.Pincus,M.D.,Ph.D.

January 16, 2004. Patent Number: US2004/001196

CLINICAL TRIAL EXPERIENCE:

Designed and led the following investigator initiated trials as Principal Investigator:

1.     Sipuleucel-T and Stereotactic Ablative Body Radiation (SAbR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC); NCT01818986. Funded by Dendreon Corporation.

2.     High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer; NCT01896271. Funded by Prometheus Laboratories.

3.     Stereotactic Ablative Body Radiation Therapy for Patients with Primary Renal Cancer. NCT02141919. Funded by a peer-reviewed grant from ACS: ACS Research Scholar Grant.

4.     Safety Lead-in Phase II Trial of Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC. NCT02473536

5.     Phase I Clinical Trial of Stereotactic Ablative Radiotherapy (SAbR) of Pelvis and Prostate Targets for Patients with High Risk Prostate Cancer. NCT02353819.

6.     Phase II Trial of Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) versus Nivolumab Alone for Metastatic Clear Cell Renal Cell Carcinoma. NCT02781506.

7.     Phase II Randomized Trial of Pazopanib Vs. Local Therapy for Renal Cell Carcinoma Patients with Limited Metastases. NCT02956798

Institutional PI of the following NRG clinical trials:

1. RTOG 924: Androgen depravation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: A phase III randomized trial.
2. RTOG 815: Phase III prospective randomized trial of dose –escalated radiotherapy with or without short-term androgen depravation therapy for patients with intermediate-risk prostate cancer.
3. RTOG 1115: Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT)with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer
4. RTOG 534: A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy
5. RTOG 126: A Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer
6. RTOG 521: A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer
    
   Co-PI and active participant in multiple cancer therapeutic trials:
   STU 072010-050, STU 092013-013, STU 082011-002, STU 072010-094, STU 072010-052, STU 072015-013, STU 042011-050, STU 082013-032, STU 072010-134, STU 072010-015, STU 072010-019, STU 072015-076.

Others:

• Active member of NRG Oncology, GU core committee member
• Member of the NCI’s Renal Cancer Task Force
• Registered member of Cancer Trials Support Unit (CTSU), NCI.

BIBLIOGRAPHY

Peer-Reviewed Publications:

Michl J, Scharf B, Schmidt A, Huynh C, Hannan R, von Gizycki H, Friedman FK, Brandt-Rauf P, Fine RL, Pincus MR, PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer, 2006. 119(7): p. 1577-85.   PMID:16688716

Bowne WB, Sookraj KA, Vishnevetsky M, Adler V, Sarafraz-Yazdi E, Lou S, Koenke J, Shteyler V, Ikram K, Harding M, Bluth MH, Ng M, Brandt-Rauf PW, Hannan R, Bradu S, Zenilman ME, Michl J, Pincus MR. The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol, 2008. 15(12): p. 3588-600.   PMID:18931881

Yaparpalvi R, Hannan R, Landau E, Kahan N, Bodner W, Kuo HC, Minsky L, Mehta KJ, Garg MK, Kalnicki S, Guha C. Timing of postseed imaging influences rectal dose-volume parameters for cesium-131 prostate seed implants. Brachytherapy. 2011 Aug 23.   PMID:21868289

Hannan R, Zhang H, Wallecha A, Singh R, Lu L, Cohen P, Alfieri A, Rothman J and Guha C.  Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer Immun. Immunother. 2012 May 27. PMID: 22644735.

Hannan R, Thompson R, Spierer M, Chen Y, Kabarriti R, Skinner W,  Chen C, Bernstein K, Landau E, Miller E, Hong L, Kalnicki S. Hypofractionated Breast Radiation therapy: Does Breast Size Matter? Int J Radiat Oncol Biol Phys. 2012 Apr 27. PMID:22543209.

Jacobs CD, Chun SG, Yan J, Xie XJ, Pistenmaa DA, Hannan R, Lotan Y, Roehrborn CG, Choe KS, Kim DN.  Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy.  Cancer Biol Ther. 2014 Mar 21;15(6). PMID:  24658086

Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R, Kalnicki S, Guha C, Garg MK. Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure. Practical Radiation Oncology. Epub 22 Feb 2014. PMID: 25407863

Huelsmann L, Kim DNW, Hannan R, Watumull LM, Brugarolas J, Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma, Clinical Genitourinary Cancer, Epub 2014 Dec 20. PMID 25620636

Hannan R, Margulis V, Chun S, Cannon N, Kim DNW, Abdulrahman RE, Sagalowsky A, Pedrosa I, Brugarolas J, Timmerman RD.  Stereotactic Radiation Therapy of Renal Cancer Inferior Vena Cava Tumor Thrombus. Cancer Biology and Therapy. Epub 2015 Mar 24:0. PMID 25800036

Meyer J, Foster R, Lev-Cohain N, Yokoo T, Dong Y,  Schwarz R, Rule W, Tian J, Xie Y, Hannan R, Nedzi L, Solberg T, Timmerman R. A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases.  Annals of Surgical Oncology. 12 May 2015. PMID 25963478

Jacobs C, Tumati V, Kapur P, Yan J, Xie XJ, Hannan R, Hsieh JT, Kim DW, Saha D. Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy. Cancer Med. 2015 Oct 16. PMID: 26471467

Ishihara D, Iyengar P, Meyer J, Timmerman R, Choy H, Hannan R. The Combination of Radiation Therapy and Immunotherapy for Genitourinary Cancer Treatment: Rationale, Current Evidence, and Prospects. Journal of Radiation Oncology. 5 Dec 2015, p1-9.

Hannan R, Tumati V, Xie X, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim, DWN, Pistenmaa D, Lotan Y, Timmerman RD. Stereotactic Body Radiation Therapy for Low and Intermediate Risk Prostate Cancer—5 Year Outcomes. European Journal of Cancer. 29 March 2016. PMID 27035363

Takeshima T, Pop LM, Laine A, Iyengar P, Vitetta E, Hannan R. Key role for Neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF. PNAS. 20 Sept 2016. PMID:27651484  

Ishihara D, Pop L, Takeshima T, Iyengar P, Hannan R. The Combination of Radiation Therapy and Immunotherapy for Cancer Treatment: Rationale, Current Evidence, and Prospects. Cancer Immun. Immunother. 14 Oct 2016. PMID 27743027.

Wang CJ, Christie A, Lin M, Jung M, Weix D, Kim DWN, Huelsmann L, Kuhn K, Pedrosa I, Margulis V, Desai N, Sagalowsky A, Cadeddu J, Gahan J, Lotan Y, Laine A, Choy H, Xie XJ, Brugarolas J, Timmerman R, Hannan R. Safety and Efficacy of Stereotactic radiotherapy for renal cell carcinoma extracranial metastases. Int J Radiat Oncol Biol Phys.1May 2017. PMID 28587057.

Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. Wang, C. J.; Christie, A.; Lin, M. H.; Jung, M.; Weix, D.; Huelsmann, L.; Kuhn, K.; Meyer, J.; Desai, N.; Kim, D. W. N.; Pedrosa, I.; Margulis, V.; Cadeddu, J.; Sagalowsky, A.; Gahan, J.; Laine, A.; Xie, X. J.; Choy, H.; Brugarolas, J.; Timmerman, R.; Hannan, R., Int J Radiat Oncol Biol Phys 2017, 98 (1), 91-100.

A new method to reconstruct intra-fractional prostate motion in volumetric modulated arc therapy. Chi, Y.; Rezaeian, N. H.; Shen, C.; Zhou, Y.; Lu, W.; Yang, M.; Hannan, R.; Jia, X., Phys Med Biol 2017, 62 (13), 5509-5530.

Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials. Jones, R. T.; Hassan Rezaeian, N.; Desai, N. B.; Lotan, Y.; Jia, X.; Hannan, R.; Kim, D. W. N.; Hornberger, B.; Dubas, J.; Laine, A. M.; Zelefsky, M. J.; Timmerman, R. D.; Folkert, M. R., Med Dosim 2017, 42 (4), 341-347.

Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. Jackson, W. C.; Desai, N. B.; Abugharib, A. E.; Tumati, V.; Dess, R. T.; Lee, J. Y.; Zhao, S. G.; Soliman, M.; Folkert, M.; Laine, A.; Hannan, R.; Zumsteg, Z. S.; Sandler, H.; Hamstra, D. A.; Montgomery, J. S.; Miller, D. C.; Kozminski, M. A.; Hollenbeck, B. K.; Hearn, J. W.; Palapattu, G.; Tomlins, S. A.; Mehra, R.; Morgan, T. M.; Feng, F. Y.; Spratt, D. E., BJU Int 2017, 120 (3), 351-357.

Radiation and RCC: Will New Data Crush the Myth of Radioresistance? R. Hannan; Kidney Cancer Journal; Volume 15 (3). 2017.

Safety and Efficacy of Concurrent Immune Checkpoint Inhibitors and Hypofractionated Body Radiotherapy. Mohamad, O.; Leon, A.; Schroeder, S.; Leiker, A.; Christie, A; Zhang-Velten, E.; Trivedi, L.; Khan, S.; Desai, N.B.; Laine, A.; Albuquerque, K.; Iyengar, P.; Arriaga, Y.; Courtney, K.; Gerber, D.; Hammers, H.; Choy, H.; Timmerman, R.; Brugarolas, J.; Hannan, R. OncoImmunology, 13 Feb 2018.

PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. Tang, H.; Liang, Y.; Anders, R. A.; Taube, J. M.; Qiu, X.; Mulgaonkar, A.; Liu, X.; Harrington, S. M.; Guo, J.; Xin, Y.; Xiong, Y.; Nham, K.; Silvers, W.; Hao, G.; Sun, X.; Chen, M.; Hannan, R.; Qiao, J.; Dong, H.; Peng, H.; Fu, Y. X., J Clin Invest 2018, 128 (2), 580-588.

Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study. Tumati, V.; Jackson, W. C.; Abugharib, A. E.; Raj, G.; Roehrborn, C.; Lotan, Y.; Courtney, K.; Bagrodia, A.; Gahan, J. C.; Zumsteg, Z. S.; Folkert, M. R.; Laine, A. M.; Hannan, R.; Spratt, D. E.; Desai, N. B., BJU Int 2018, 121 (3), 365-372.

Wang, T, Lu, R, Kapur, P, Jaiswal, B, Hannan, R, Zhang, Z, Pedrosa, I, Luke, J, Zhang, H, Goldstein, L, Yousuf, Q, Gu, Y, McKenzie, T, Joyce, A, Kim, M, Wang, X, Luo, D, Onabolu, O, Xie, Z, Chen, M, Filatenkov, A, Torrealba, J, Luo, X, Guo, W, He, J, Stawiski, E, Modrusan, Z, Durinck, S, Seshagiri, S, and Brugarolas, J. An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. (2018) Cancer Discovery.

Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study.

Woldu SL; Matulay JT; Clinton TN; Singla N; Freifeld Y; Sanli O; Krabbe L; Hutchinson RC; Lotan Y; Hammers H; Hannan R; Brugarolas J; Bagrodia A; Margulis V

PMID: 30217763 Clin Genitourin Cancer (2018)

PhD Dissertation Thesis:

            Hannan R. PaCa-Ag1: A candidate pancreatic cancer-specific tumor marker.  A thesis accepted by SUNY Downstate graduate school in partial fulfillment of the requirements of Doctor of Philosophy. June 2003.

Selected Abstract publication:

         D. Ishihara, K. Louder, M. Akter, C. Ahn, V. Margulis, Y. Arriaga, K. Courtney, R. D. Timmerman, J. Brugarolas, and R. Hannan; Phase 2 Trial of High-Dose Interleukin-2 (IL-2) and Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)—Interim Analysis of i-SAbR IL-2 Trial;PMID: 27743027

Takeshima T, Vitetta E, Hannan R. Anti-tumor characteristics of radiation-induced tumor-infiltrating neutrophils. J Immunother Cancer. 2014; 2(Suppl 3): P162.

         R. Hannan, J. Shan, S. Gandhi, K. Bernstein, D. Blakaj, C. Montagna, T. Tong, S. Kalnicki, M. Garg, C. Guha.  TMPRSS2-ERG Loci Abnormality in Salvage Radiation Therapy (sRT) Refractory Prostate Cancer Patients. IJROBP,  1 October 2011 (Vol 81, Issue 2, Supplement , Page S761)

R. Hannan, P. Cohen, L. Lu, H. Zhang, S. Saha, R. Kabarriti, A. Alfieri, M. Garg, S. Kalnicki, C. Guha. A Novel Combination of Listeria PSA Vaccine and Radiation Therapy for Prostate Cancer (PC). IJROBP, 1 November, 2010 (Vol. 78, Issue 3, Supplement, pS642-S643)

R. Hannan, J. Rossinow, Y. Chen, R. Kabarri, W. Skinner, E. M. Landau, C. Guha, S. Kalnicki, M. Garg. PSA trend before and during salvage radiation therapy: Prognostic factor for biochemical control. J Clin Oncol Vol 28, No 15 (May 20 Supplement), 2010: e15048

R. Hannan, M. Spierer, Y. Chen, R. Kabarriti, W. Skinner, K. Bernstein, E. Landau, E. Miller, L. Hong, S. Kalnicki. Impact of chemotherapy on radiation toxicity in hypofractionated breast radiation therapy. 2009 ASCO: Breast Cancer Symposium   Abstract No: 297

R. Hannan, N. Thawani, R. Yaparpalvi, J. Lin, G. Kuo, M. Biagioli, L. Hong, S. Kalnicki, S. Mutyala. Recommendations on Organs at Risk Reporting Volumes for Cervix HDR Brachytherapy Based on Intra-fraction Variations of DVH.   IJROBP.  1 Sept 2008 (Vol. 72, Issue 1, Pg S360)

         R. Hannan , M. Spierer, W. Skinner, R. Kabarriti, C. Chen, K. Bernstein, E. Landau, E. Miller, L. Hong, S. Kalnicki. Hypofractionated Whole Breast Radiation Therapy for Large-breasted Patients.  IJROBP. 1 Nov 2009 (Vol. 75, Issue 3, Supplement, Pages S223-S224)

R. Hannan, J. Khutoretskya, A Jones, S Bradu, R Huyhn, H von Gyszecki, B Scharf, M Pincus and J, Michl. 2003. Immuno-therapeutic application of novel pancreatic cancer-specific tumor marker PaCa-Ag1. European Journal of Cancer, 1 (Suppl.):S19    

R. Hannan, Y. Khutoretskya, A. Jones, S Smith, S Bradu, R Huyhn, J Koehnke, A Kolychkina,, MR Pincus and J Michl. 2003. PaCa-Ag1, A candidate Pancreatic Cancer (PaCa)-specific tumor marker. Proceedings American Association Cancer Research, 44:360

R. Hannan, Y. Khutoretskya, A. Jones, S. Smith, S. Bradu, R. Huyhn,J. Koehnke, A. Kolychkina,, M.R. Pincus and J. Michl. 2003. PaCa-Ag1, A candidate Pancreatic Cancer (PaCa)-specific tumor marker. Molecular Biology of the Cell

R. Hannan, J. Koehnke, S. Bradu, A. Kolychkina, J. Khutoretskya, A.Jones, P.C. Nemes, M.R. Pincus and J. Michl.2002.PaCa-Ag1: Isolation and cloning of a marker for pancreatic cancer. Molecular Biology of the Cell, 13(Suppl.):137a

R. Hannan, S.M. Bradu, J.R. Jagdeo, B. Sang, A. Kolychkina, J.Saukin, J.S. Jagdeo, P.C. Nemes, J. Koehnke, B. Scharf, M.R. Pincus and J. Michl. 2002. Pancreatic cancer associated antigen: Novel diagnostic and therapeutic gateway. Proceedings American Association Cancer Research, 43:84